CSL Stock Overview
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
CSL Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$278.97 |
52 Week High | AU$312.99 |
52 Week Low | AU$228.65 |
Beta | 0.29 |
1 Month Change | -0.70% |
3 Month Change | -4.27% |
1 Year Change | -8.34% |
3 Year Change | 3.95% |
5 Year Change | 40.49% |
Change since IPO | 34,771.60% |
Recent News & Updates
Recent updates
Does CSL (ASX:CSL) Have A Healthy Balance Sheet?
Mar 19CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors
Feb 02Is CSL (ASX:CSL) Using Too Much Debt?
Dec 10CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate
Nov 16These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well
Sep 11CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price
Aug 13CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet
May 30A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)
May 09Does CSL (ASX:CSL) Have A Healthy Balance Sheet?
Mar 01Estimating The Fair Value Of CSL Limited (ASX:CSL)
Feb 07CSL (ASX:CSL) Seems To Use Debt Quite Sensibly
Nov 17CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate
Oct 27We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt
Aug 19Is CSL Limited (ASX:CSL) Trading At A 22% Discount?
Jul 29CSL's (ASX:CSL) Problems Go Beyond Weak Profit
Feb 22Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?
Jan 19With EPS Growth And More, CSL (ASX:CSL) Is Interesting
Dec 08CSL (ASX:CSL) Seems To Use Debt Quite Sensibly
Oct 26We Think Shareholders Will Probably Be Generous With CSL Limited's (ASX:CSL) CEO Compensation
Oct 05Here's Why We Think CSL (ASX:CSL) Is Well Worth Watching
Sep 02CSL Limited (ASX:CSL) Shares Could Be 30% Above Their Intrinsic Value Estimate
Jul 22CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet
Jul 01Do CSL's (ASX:CSL) Earnings Warrant Your Attention?
May 20We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt
Mar 29Shareholder Returns
CSL | AU Biotechs | AU Market | |
---|---|---|---|
7D | 1.6% | -4.2% | -3.0% |
1Y | -8.3% | -10.2% | 3.9% |
Return vs Industry: CSL exceeded the Australian Biotechs industry which returned -10.2% over the past year.
Return vs Market: CSL underperformed the Australian Market which returned 3.9% over the past year.
Price Volatility
CSL volatility | |
---|---|
CSL Average Weekly Movement | 2.6% |
Biotechs Industry Average Movement | 11.5% |
Market Average Movement | 8.9% |
10% most volatile stocks in AU Market | 17.2% |
10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: CSL has not had significant price volatility in the past 3 months.
Volatility Over Time: CSL's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1916 | 32,065 | Paul McKenzie | www.csl.com.au |
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
CSL Limited Fundamentals Summary
CSL fundamental statistics | |
---|---|
Market cap | AU$134.81b |
Earnings (TTM) | AU$3.83b |
Revenue (TTM) | AU$21.98b |
35.2x
P/E Ratio6.1x
P/S RatioIs CSL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CSL income statement (TTM) | |
---|---|
Revenue | US$14.18b |
Cost of Revenue | US$6.86b |
Gross Profit | US$7.32b |
Other Expenses | US$4.85b |
Earnings | US$2.47b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 13, 2024
Earnings per share (EPS) | 5.12 |
Gross Margin | 51.63% |
Net Profit Margin | 17.43% |
Debt/Equity Ratio | 54.4% |
How did CSL perform over the long term?
See historical performance and comparison